Following the rebalancing of the S&P Quality Aristocrats last Friday, the following stocks were removed from or added to my two ETF indices (50% weighting):

New additions:

$QDEV (+0,16%): $NOVN (-0,92%) , $REL (+1,13%) , $ITX (+1,51%) , $LSEG (+4,15%) , $DB1 (+1,48%) and more

$QUS5 (+0,53%): $BKNG (+0,79%) , $MRK (+0,33%) , $CRM (-0,31%) , $UNP (-1,36%) , $COR (+1,21%) , $CAH (+3,92%) and more

Kicked out of both indices and therefore according to S&P no longer Quality Aristocrats are among others: $BATS (-0,17%) , $7974 (-1,81%) , $HD (+0,44%) , $LOW (-0,48%) , $HLT (+0,85%)

In addition, the allocation of all individual stocks in the indices was reduced again to max. 5 % was limited.

Thanks to the recent rally of $$HY9H (+7,43%) my current top 10 weighting (ETFs+shares) is as follows:

3.48% Alphabet

3.04% SK Hynix

3.04% Broadcom

2.93% Meta

2.75% Microsoft

2.71% Apple

2.71% NVIDIA

2.55% Taiwan Semiconductor

2.13% Mastercard

2.08% Visa

New portfolio key figures:

P/E: 27.1 (<30) 🟢

Forward P/E: 21.1 (<25) 🟢

P/Β: 11.5 (<5) 🔴

EV/FCF: 28.7 (<25) 🟡

ROE: 42% (>15%) 🟢

ROIC: 19% (>15%) 🟡

EPS growth for the next 5 years: 15% (>7%) 🟢

Sales growth for the next 5 years: 9% (>5%) 🟡

My internal rate of return is currently 20.19%

$COR (+1,21%)

I am invested and the share has achieved good results. Analysts tend to recommend buying. According to sites like aktienfinder, there is an overvaluation that the share could grow into. But what is your general assessment? Is the economic performance weakening? Has anyone already sold a share? Will there be laws in the future to sustainably reduce healthcare costs? A law that is aimed more at the mediation structure is in the works

Yesterday struck again and expanded position.

Stable performance despite weak market

Yesterday was the day.

First position opened.😁

Was already so long on the WL.

$ABC (+1,21%) I would be interested to know if anyone here knows this company better and what you say about it. I think the growth rates are very strong and the chart looks wonderful. Especially since they make a turnover of 238,59Mrd$ with a market capitalization of 36Mrd$. Now comes the point that I can't quite put my finger on. The company has a net profit margin of only 0.71% in fiscal 2022, would this be acceptable to you given the growth or is the risk of an operating loss too high?

In addition, the debt is relatively high